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Conditionally replicating HIV-1 variants that can be switched on and off at will are attractive tools for HIV
research. We previously developed a genetically modiﬁed HIV-1 variant that replicates exclusively when
doxycycline (dox) is administered. The nef gene in this HIV-rtTA variant was replaced with the gene
encoding the dox-dependent rtTA transcriptional activator. Because loss of Nef expression compromises
virus replication in primary cells and precludes studies on Nef function, we tested different approaches to
restore Nef production in HIV-rtTA. Strategies that involved translation via an EMCV or synthetic internal
ribosome entry site (IRES) failed because these elements were incompatible with efﬁcient virus repli-
cation. Fusion protein approaches with the FMDV 2A peptide and human ubiquitin were successful and
resulted in genetically-stable Nef-expressing HIV-rtTA strains that replicate more efﬁciently in primary T-
cells and human immune system (HIS) mice than Nef-deﬁcient variants, thus conﬁrming the positive
effect of Nef on in vivo virus replication.
& 2015 Elsevier Inc. All rights reserved.Introduction
The Nef protein encoded by the primate lentiviruses - human
immunodeﬁciency virus type 1 and 2 (HIV-1, HIV-2) and simian
immunodeﬁciency virus (SIV) - is considered to be an accessory
protein, because it is dispensable for viral replication in T cell lines
but contributes to efﬁcient replication and disease progression in
HIV-1 infected individuals and SIV-infected macaques. Nef inter-
acts with various cellular proteins and a multitude of Nef activities
have been described, including down-modulation of surface
expression of CD4 and MHC-I in infected cells and counteracting
cellular restriction factors (Basmaciogullari and Pizzato, 2014;
Fackler et al., 2006; Kirchhoff et al., 2008; Rosa et al., 2015; Usami
et al., 2015).
Inactivation of Nef results in attenuated HIV and SIV variants
that yield a reduced viral load upon infection (Gibbs et al., 1994;
Kestler et al., 1991; Watkins et al., 2013; Zou et al., 2012). Because
attenuated viruses can be very effective in inducing protective
immunity against pathogenic viruses (e.g. smallpox, polio andVirology, Academic Medical
msterdam, the Netherlands.measles virus), Nef-deleted HIV and SIV variants were considered
as prophylactic vaccine candidate. Vaccination of macaques with
such SIV variants does indeed provide robust protection against a
challenge with pathogenic strains (reviewed in (Desrosiers, 1998;
Johnson, 1999; Mills et al., 2000)). However, the attenuated vac-
cine virus persists and can revert to virulence, which caused dis-
ease in a minority of the vaccinated animals (Baba et al., 1995,
1999; Chakrabarti et al., 2003; Whatmore et al., 1995). Also some
of the long-term survivors of the Sydney Blood Bank Cohort
infected with a natural Nef-deﬁcient HIV-1 variant did eventually
progress to AIDS (Zaunders et al., 2011). Furthermore, an HIVΔ3
variant with deletions in the nef, vpr and LTR sequences regained
substantial replication capacity in long-term cell culture infections
by acquisition of compensatory changes elsewhere in the viral
genome (Berkhout et al., 1999). These results highlight the genetic
instability and evolutionary capacity of attenuated HIV and SIV
strains, which poses a serious safety risk for the application of live-
attenuated HIV vaccines in humans.
We and others previously presented a Nef-deleted HIV-1 variant
that replicates in the presence of doxycycline (dox) but not in the
absence of this antibiotic (Berkhout et al., 2002; Das et al., 2002,
2004a; Smith et al., 2001; Verhoef et al., 2001). In this HIV-rtTA
variant, the Tat-TAR regulatory mechanism that normally controls
viral gene expression was inactivated by mutation of both the Tat
gene and the TAR RNA structure, and functionally replaced by the
Fig. 1. HIV-rtTA constructs. (A) Schematic of the HIV-1 proviral DNA genome with
the LTR region subdivided in U3, R and U5 domains. The nef gene overlies the TPI
region, which consists of the T-rich sequence, polypurine tract (ppt), and attach-
ment/integration sequence (att/int). (B) In HIV-rtTA, the Tat-TAR axis of tran-
scription regulation has been inactivated by a Tyr-26-Ala substitution in Tat (Tatmut)
and multiple nucleotide substitutions in the bulge and loop of TAR (TARmut).
Transcription and replication of the virus was made dox-dependent by the intro-
duction of tetO elements in the U3 promoter region and replacing the nef gene by
the rtTA gene. Furthermore, a 198-nt fragment of the nef/U3 sequence downstream
of the TPI region was deleted to reduce the genome size. (C) In the HIV-rtTA-nef
variants, the wild-type nef, TPI and U3 sequences were restored. The rtTA and nef
genes were separated by the 25-amino acid 2A sequence, the 76-amino acid Ub
sequence or the 585-nt EMCV IRES element (indicated with IRES). (D) Nef and rtTA
protein products resulting from the rtTA-2A-nef, rtTA-Ub-nef and rtTA-IRES-nef
conﬁguration. (E) In the HIV-nef-rtTA variants, the nef gene with a mutated TPI
sequence (TPImut) was introduced downstream of the env gene and the U3 region
was further truncated by deleting all nef/U3 sequences downstream of the TPI
(from the EcoRV site at U3 position 35) and upstream of the tetO sites. The nef and
rtTA genes were separated by the 25-amino acid 2A sequence, the EMCV IRES
element or the 50-nt PS3 IRES element (indicated with PS3). (F) Nef and rtTA
protein products resulting from the nef-2A-rtTA, nef-IRES-rtTA and nef-PS3-rtTA
conﬁguration.
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and Bujard, 2000). The rtTA gene encoding a man-made tran-
scriptional activator was inserted in place of the nef gene and tet-
operator (tetO) DNA binding sites were inserted into the LTR pro-
moter. Since the rtTA protein can only bind tetO and activate
transcription in the presence of dox, HIV-rtTA replicates exclusively
when dox is administered. The HIV-rtTA variant has been improved
signiﬁcantly by virus evolution (Das et al., 2004b; Marzio et al.,
2001; Marzio et al., 2002; Zhou et al., 2006a, 2006b, 2006c) and we
have demonstrated dox-dependent replication in vitro in T cell
lines, ex vivo in human lymphoid tissue (Kiselyeva et al., 2004) and
in vivo in humanized mice (Legrand et al., 2012).
In principle, the conditional replication feature may improve
the safety of a live-attenuated virus vaccine because replication
can be temporarily activated by dox to the extent needed for
induction of the immune system. Subsequent dox-withdrawal will
stop viral gene expression and replication, which should prevent
evolution of the vaccine virus toward a pathogenic variant.
Application of a conditionally replicating HIV-rtTA as a vaccine in
humans will require additional safety measures. Safety could be
increased by the inclusion of an additional drug-dependent con-
trol mechanism (Das et al., 2005) and by deletion of the integrase
(IN) function. Because IN-deﬁcient HIV-1 variants do not replicate
in most cell lines and primary cells (Nakajima et al., 2001), an
alternative replication mechanism, like the simian virus 40 repli-
cation signals, should be integrated (Lu et al., 2004). An efﬁciently
replicating, drug-controlled and non-integrating HIV-1 variant has
however not yet been developed.
Nevertheless, the dox-controlled HIV-rtTA and a similar SIV
variant (Das et al., 2007, 2008) can be used in vaccination studies
in laboratory animals to learn - for example - whether continuous
low-level replication, which is typical for a regular live-attenuated
virus, is required for protection and what protective correlates are
induced by an effective vaccine (Manoussaka et al., 2013). Fur-
thermore, these viruses can be used in cell culture and animal
experiments to study HIV-1 and SIV biology. Because the nef gene
was replaced with the rtTA gene, HIV-rtTA will however replicate
suboptimally in primary cells and in vivo. HIV-rtTA did indeed
demonstrate an attenuated phenotype when tested in a huma-
nized mouse model of hematopoiesis that harbors all major
components of the human immune system (HIS) (Legrand et al.,
2012). Although infection of dox-fed HIS mice resulted in the
establishment of a productive infection, HIV-rtTA replication was
delayed compared to the parental X4-tropic HIV-1 LAI strain and
was not accompanied by CD4þ T-cell depletion (Legrand et al.,
2012). In vaccination studies, this attenuated phenotype is likely to
restrict the induction of protective immune responses (Lohman et
al., 1994; Wyand et al., 1996). The vaccine response may also be
suboptimal as no response against Nef will be induced. We
therefore considered different approaches to construct a Nef-
positive HIV-rtTA variant. This study resulted in HIV-rtTA-nef
variants that express all HIV-1 proteins, which can be used for
future vaccination studies in the humanized mouse model (An et
al., 2007). These virus variants can also be used as a research tool
for studying the Nef protein function.Results
Design of Nef-positive HIV-rtTA variants
The nef gene is positioned at the 30 end of the HIV-1 genome
and partially overlaps the U3 sequence of the 30 LTR (Fig. 1A).
Moreover, the nef gene overlies the T-rich sequence (T) and the
polypurine tract (PPT), which are important motifs for reverse
transcription of the RNA genome into a DNA copy, and the
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integration of the viral DNA into the cellular genome to establish
the provirus. We collectively refer to these replication signals as
TPI element (Fig. 1A). In the dox-controlled HIV-rtTA variant, the
nef sequence upstream of the TPI was replaced by the rtTA gene,
such that the rtTA protein is produced from the spliced RNA
transcript that encodes Nef in wild-type HIV-1 (Fig. 1B). Further-
more, the nef sequence overlapping the U3 region was partially
deleted to reduce the genome size, but the TPI was maintained.
The extent of this deletion was based on U3 deletions previously
observed in Nef-minus natural HIV-1 variants (Das et al., 2004a;
Verhoef et al., 2001).
To restore Nef production in HIV-rtTA, the complete nef gene
can be placed downstream or upstream of the rtTA gene (rtTA-nef
and nef-rtTA conﬁguration, respectively; Fig. 1C and E). We tested
both conﬁgurations to increase the chance of obtaining a virus
with an optimal Nef and rtTA expression proﬁle. All nef sequences,
including the TPI and U3 elements, will be present at their original
position at the 3’ end of the viral genome in the rtTA-nef conﬁg-
uration (Fig. 1C). The nef-rtTA conﬁguration will result in dupli-
cation of the TPI and nef/U3 sequences (Fig. 1E), which may affect
viral replication. First, the presence of two TPI sites may cause
aberrant reverse transcription as second-strand DNA synthesis can
initiate at both PPT sites (Munch et al., 2005). Second, the nef/U3
sequence repeat may trigger recombination-mediated deletion of
the intervening sequences from the viral genome (An and Tele-
snitsky, 2002; Marzio et al., 2001). To prevent these problems, we
inactivated the TPI sequence in the Nef open reading frame (ORF)
by synonymous mutations that do not affect the Nef protein
sequence (TPImut in Fig. 1E) (Munch et al., 2005) and we mini-
mized the U3 promoter region in the nef-rtTA constructs (Fig. 1E).
In both conﬁgurations, the rtTA and Nef ORF will be jointly present
on the mRNA species that encodes Nef in wild-type HIV-1. Nor-
mally, only the 50-positioned ORF will be translated efﬁciently. We
therefore tested different approaches to allow translation of both
ORFs from a bicistronic transcript.
In the 2A-fusion protein approach, the rtTA and Nef ORFs were
placed in frame and connected by the 25-amino acid 2A sequence
from foot-and-mouth disease virus (FMDV). The 2A sequence is
thought to cause a translational recoding event in which the for-
mation of a peptide bond between the penultimate glycine and
ultimate proline in the 2A sequence is skipped during elongation
(Doronina et al., 2008a, 2008b). As a consequence, the nascent N-
terminal protein will be released while translation of the C-
terminal protein continues. The rtTA-2A-nef conﬁguration
(Fig. 1C) will thus result in an rtTA protein with 24 2A-derived
amino acids at its C-terminus (rtTA-2A), and a Nef protein with a
2A-derived proline at its N-terminus (ProNef; Fig. 1D). As the
additional amino acids may affect rtTA or Nef function, we also
tested the nef-2A-rtTA conﬁguration (Fig. 1E), which will result in
the addition of the 24 2A-derived amino acids to the C-terminus of
Nef (Nef-2A), and the proline extension at the N-terminus of rtTA
(PrortTA; Fig. 1F).
In the ubiquitin (Ub)-fusion protein approach, the rtTA and Nef
ORFs were placed in frame and connected by the 76-amino acid Ub
sequence (Fig. 1C). Fusion proteins containing the Ub domainwill be
co-translationally cleaved by Ub-speciﬁc proteases (Varshavsky,
2005). This cleavage occurs between the C-terminal amino acid of
Ub and the N-terminal amino acid of the downstream protein. The
rtTA-Ub-nef conﬁguration will thus leave 76 Ub-derived amino
acids at the C-terminus of rtTA (rtTA-Ub; Fig. 1D), but a wild-type
Nef protein will be synthesized. We did not test the nef-Ub-rtTA
conﬁguration because this arrangement would result in the pro-
duction of a Nef-Ub fusion protein.
We also tested an internal ribosome entry site (IRES)-based
approach in which translation of the downstream ORF is driven bythe 585-nt IRES element from encephalomyocarditis virus (EMCV)
(Jang et al., 1989; Kaminski et al., 1990). This approach will result in
the synthesis of both wild-type proteins (Fig.1C and D). Because the
IRES and downstream ORF will be present at the 30 end of all spliced
and unspliced viral RNAs, the rtTA-IRES-nef conﬁguration may
result in an aberrant level and timing of Nef production. We
therefore also tested the nef-IRES-rtTA conﬁguration (Fig. 1E and F).
We anticipated that the introduction of the large, highly structured
IRES domain in the viral RNA could affect other processes during
viral replication, for example splicing of the transcripts, packaging
of the genomic RNAs into virion particles or reverse transcription of
these RNAs. For this reason, we also constructed virus variants with
a “synthetic” 50-nt IRES element (PS3; (Venkatesan and Dasgupta,
2001)). Unfortunately, we could only test the nef-PS3-rtTA conﬁg-
uration because several attempts to generate the molecular clone of
the rtTA-PS3-nef variant were unsuccessful.
Gene expression proﬁle of the new HIV-rtTA variants
To analyze viral protein production, 293T human embryonic
kidney cells were transfected with the different HIV-rtTA plasmids
and cultured without or with dox for 48 h. We ﬁrst measured the
production of the viral CA-p24 protein in the culture supernatant
(Fig. 2A). The CA-p24 level was very low when the cells were
cultured without dox, which conﬁrms that gene expression of all
variants is controlled by rtTA and dox. In the presence of dox, CA-
p24 production of the rtTA-2A-nef, rtTA-Ub-nef, rtTA-IRES-nef,
nef-2A-rtTA and nef-PS3-rtTA variants was similar to that of the
control HIV-rtTA, whereas a 4-fold reduced CA-p24 level was
measured for the nef-IRES-rtTA construct (data summarized in
Table 1). To measure rtTA activity, the HIV-rtTA constructs were
co-transfected with the pLTR-2ΔtetO-lucff reporter plasmid in
which the luciferase gene is controlled by a dox/rtTA-inducible
tetO promoter (Das et al., 2004b). The luciferase level measured
after two days of culturing with dox is a measure of the rtTA
activity and reﬂects the rtTA production level. The rtTA activity of
the new variants did not differ signiﬁcantly from that of the ori-
ginal HIV-rtTA, except for the rtTA-Ub-nef conﬁguration that
demonstrated an almost 2-fold reduction (Fig. 2B). Remarkably,
the nef-IRES-rtTA construct that showed a severe CA-p24 pro-
duction defect demonstrated normal rtTA activity.
We next analyzed Nef protein production by western blot ana-
lysis of the cells transfected with the HIV-rtTA plasmids (Fig. 2C).
The wild-type HIV-1 LAI construct that produces the 206-amino
acid Nef protein was included as a positive control. Whereas the
original HIV-rtTA construct did not encode Nef, all new HIV-rtTA
variants did express the protein, although the level and size varied
considerably. The lowest level was observed for the 2A constructs
and the highest level for the rtTA-IRES-nef construct. The Nef-2A
product of the nef-2A-rtTA construct demonstrated the expected
size increase due to the C-terminal extension. Similarly, the ProNef
protein of the rtTA-2A-nef construct showed a small size increase
due to the N-terminal extension. The size of Nef produced by rtTA-
Ub-nef was identical to that of the wild-type protein produced by
HIV-1 LAI, which conﬁrms that the rtTA-Ub sequence is completely
removed. As expected, the nef-IRES-rtTA, rtTA-IRES-nef and nef-
PS3-rtTA constructs produced the wild-type Nef protein. An addi-
tional larger Nef product was observed for the rtTA-IRES-nef con-
struct, which likely results from usage of the translation start codon
that is present 12-nt upstream of the Nef ORF in the EMCV IRES
sequence (Jang et al., 1989; Kaminski et al., 1990).
Replication of the Nef-expressing HIV-rtTA variants
SupT1 T cells were transfected with the HIV-rtTA plasmids and
cultured with dox to determine the replication capacity of the
Nef
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Fig. 2. Gene expression of new HIV-rtTA variants. The production of CA-p24 (A), rtTA
(B) and Nef proteins (C) was analyzed in 293 T cells transfected with the different
HIV-rtTA plasmids. (A) Transfected cells were cultured without or with dox for 48 h
and CA-p24 in the culture supernatant was measured by ELISA. Average values
obtained in 3–6 experiments are shown, with error bars indicating the standard
error of the mean (7SEM). Statistical analyses (two-sided unpaired sample t-tests)
of the ‘plus dox’ data demonstrated that only the CA-p24 level obtained with the
HIV-nef-IRES-rtTA construct differed signiﬁcantly from the level obtained with the
HIV-rtTA plasmid (Po0.05). (B) Cells were co-transfected with the dox/rtTA-
responsive pLTR-2ΔtetO-lucff plasmid and cultured without or with dox for 48 h.
The intracellular luciferase level was subsequently measured to quantify rtTA
activity. Average values (7SEM) for 2–4 experiments are shown. Statistical ana-
lyses of the ‘plus dox’ data demonstrated that only the rtTA level obtained with the
HIV-rtTA-Ub-nef construct differed signiﬁcantly from the level obtained with the
HIV-rtTA plasmid (Po0.05). (C) Transfected cells were cultured with dox for 48 h
and Nef expression was analyzed by western blot analysis.
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replicated efﬁciently, which resulted in a rapidly spreading infec-
tion as evidenced by a fast increase in the CA-p24 level in the
culture supernatant. These Nef-positive viruses replicate similarly
(rtTA-2A-nef) or slightly delayed (nef-2A-rtTA) compared to the
Nef-negative HIV-rtTA variant, which is in agreement with Nef not
being required for HIV-1 replication in this transformed T-cell line.
The rtTA-Ub-nef variant demonstrated delayed replicationkinetics, which may be caused by the reduced rtTA level (Fig. 2B;
Table 1). All IRES-containing viruses (nef-IRES-rtTA, rtTA-IRES-nef
and nef-PS3-rtTA) also demonstrated delayed replication kinetics.
Whereas the nef-IRES-rtTA variant demonstrated a severe CA-p24
production defect (Fig. 2A), the less efﬁcient replication of the
rtTA-IRES-nef and nef-PS3-rtTA viruses did not correlate with
reduced CA-p24 or rtTA production (Fig. 2A and B). These results
indicate that the introduced IRES sequences may negatively affect
another step in the viral replication cycle.
Genetic stability of the Nef-expressing viruses
HIV-1 has a high mutation rate and we therefore tested the
genetic stability of the modiﬁed HIV-rtTA genomes. We analyzed
the rtTA and nef regions after viral passage onto fresh cells. All
virus variants were found to maintain the introduced nef and
ﬂanking sequences, except for HIV-nef-IRES-rtTA. A large deletion
in the HIV-nef-IRES-rtTA genome almost completely removed the
nef and IRES sequences and restored the original HIV-rtTA con-
ﬁguration (data not shown). This rapid evolution explains the
detection of replicating virus in the HIV-nef-IRES-rtTA culture
(Fig. 3), while the input construct demonstrated a severe defect in
CA-p24 production.
To further investigate the genetic stability of all Nef-expressing
virus variants, we started multiple independent infections of
SupT1 cells and analyzed the rtTA and nef regions in the viral
genome after 2–3 months of virus passage (data summarized in
Table 1). Analysis of the HIV-rtTA-2A-nef and HIV-rtTA-Ub-nef
cultures demonstrated the maintenance of the input virus in all
cultures. Analysis of 11 HIV-nef-2A-rtTA cultures revealed the
presence of the intact input virus in 7 cultures, while a variant
with a partial or complete deletion of the nef gene outcompeted
the input virus in 4 cultures. In all cultures of the poorly repli-
cating rtTA-IRES-nef virus a deletion was observed that included
the IRES element and nef sequences upstream of the TPI region.
Similarly, the nef-IRES-rtTA and nef-PS3-rtTA viruses consistently
lost the introduced nef-IRES and nef-PS3 sequences, respectively,
which resulted in virus variants that resemble the original HIV-
rtTA. The frequent deletion of the EMCV and PS3 IRES elements
upon long-term culturing reinforces the ﬁnding that these exo-
genous sequences inhibited virus replication (Fig. 3).
Nef produced in the rtTA-2A-nef and rtTA-Ub-nef conﬁguration
downregulates CD4 expression
HIV-rtTA-2A-nef and HIV-rtTA-Ub-nef are the most promising
variants because they express both rtTA and Nef protein, replicate in
a dox-dependent manner in T cell lines, and demonstrate genetic
stability (Table 1). We next wanted to test the capacity of the pro-
duced Nef proteins to down modulate cellular CD4 expression. Per-
forming such a functional test in the virus context is however com-
plicated by the fact that transcription of the HIV-rtTA genome
requires the rtTA protein. As shown in Fig. 2A, the rtTA activity of the
new HIV-rtTA constructs varies, which will affect Nef production.
Moreover, production of all other viral proteins will be affected,
including Vpu and Env that can also down regulate CD4 expression
(Chen et al., 1996). To avoid such complications, we made pcDNA3-
based rtTA-2A-nef and rtTA-Ub-nef plasmids in which production of
the rtTA and Nef proteins is driven by the CMV immediate early (IE)
promoter and not inﬂuenced by rtTA activity. An additional advan-
tage of using pcDNA3 instead of HIV-rtTA constructs is that a
pcDNA3-nef plasmid can be included to allow comparison with the
wild-type Nef protein. These plasmids were transfected into TZM-bl
cells and CD4 cell surface expression was measured after 48 h by
FACS analysis (Fig. 4A). Control cells were transfected with the empty
pcDNA3 vector. Transfection with an rtTA-expressing plasmid
Table 1
Characteristics of novel HIV-rtTA variants.
CA-p24 rtTA Nef Replication
Expressiona Protein Expressionb Protein Expressionc Performanced Genetic stabilitye
HIV-rtTA þþ rtTA þþ – – þþ ndf
HIV-rtTA-2A-nef þþ rtTA-2A þþ ProNef þ þþ 12/12
HIV-rtTA-Ub-nef þþ rtTA-Ub þ Nef þþ þ 24/24
HIV-rtTA-IRES-nef þþ rtTA þþ Nef þþ þ 0/13
HIV-nef-2A-rtTA þþ PrortTA þþ Nef-2A þ þ/þþ 7/11
HIV-nef-IRES-rtTA þ/ rtTA þþ Nef þþ þ 0/21
HIV-nef-PS3-rtTA þþ rtTA þþ Nef þþ þ/ 0/13
a relative CA-p24 production measured with dox in Fig. 2A.
b relative rtTA activity measured with dox in Figs. 2B and 4B.
c relative amount of Nef protein detected in western blot analysis in Fig. 2C.
d relative replication in SupT1 cells as shown in Fig. 3.
e fraction of long-term cultures in which the introduced sequences were stably maintained.
f nd, not determined.
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Fig. 3. Replication of HIV-rtTA variants. SupT1 cells were transfected with the HIV-rtTA plasmids with different rtTA-nef or nef-rtTA conﬁgurations and cultured with dox.
Replication was monitored by CA-p24 ELISA on culture supernatant samples. For comparison, we included the original HIV-rtTA (rtTA). The replication curves obtained in
2 experiments are shown.
Y.U. van der Velden et al. / Virology 488 (2016) 96–107100(pcDNA3-rtTA) did not signiﬁcantly affect the CD4 level, whereas
transfection with the wild-type Nef construct reduced the CD4 level
to approximately 30%. A similar CD4 reduction was observed for the
rtTA-2A-nef and rtTA-Ub-nef constructs, demonstrating that both
conﬁgurations produce functional Nef protein.
To conﬁrm the difference in rtTA activity produced in the rtTA-
2A-nef and rtTA-Ub-nef conﬁgurations, we measured the rtTA-
induced luciferase production in 293 T cells transfected with the
pcDNA3-based vectors and the dox/rtTA-responsive pLTR-2ΔtetO-
lucff reporter plasmid (Fig. 4B). Transfection with the rtTA and rtTA-2A-nef constructs resulted in a high dox-dependent luciferase level,
whereas a 3-fold lower activity was measured for the rtTA-Ub-nef
variant, which is in agreement with the reduced rtTA level observed
for this rtTA-Ub-nef conﬁguration when measured in the HIV-rtTA
virus context (Fig. 2B).
Nef-expression improves HIV-rtTA replication in primary T cells
We next constructed rtTA-2A-neffs and rtTA-Ub-neffs control
viruses in which Nef translationwas blocked by an early frameshift
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CMV IE promoter. The ‘empty’ pcDNA3 vector was included as control (–). The
cellular CD4 level was measured after 48 h by FACS analysis. Average values
(7SEM) for 4–6 experiments are shown. Statistical analyses (one-way ANOVAwith
Bonferroni's multiple comparison post-hoc test) demonstrated that the CD4 level
obtained with the rtTA plasmid did not differ signiﬁcantly from the level obtained
with the pcDNA3 control, whereas the level obtained with the nef, rtTA-2A-nef and
rtTA-Ub-nef plasmids did (Po0.05). The CD4 level obtained with the rtTA-2A-nef
and rtTA-Ub-nef plasmids did not differ signiﬁcantly from the level obtained with
the nef plasmid. (B) 293 T cells were transfected with the different pcDNA3 vectors
and the dox/rtTA-responsive pLTR-2ΔtetO-lucff reporter plasmid. After culturing
the cells with or without dox for 48 h, the intracellular luciferase level was mea-
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observed for the rtTA-2A-nef plasmid did not.
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Nef-negative viruses and their Nef-positive counterparts was ﬁrst
tested in the SupT1 T-cell line (Fig. 5A). The rtTA-2A-nef and rtTA-
2A-neffs viruses replicated similarly and almost as efﬁciently as the
original HIV-rtTA variant. The rtTA-Ub-nef and rtTA-Ub-neffs
viruses replicated also with comparable efﬁciency. Both Ub var-
iants replicated less efﬁciently than HIV-rtTA, which may be due to
the reduced rtTA expression (Figs. 2B and 4B). Thus, Nef inacti-
vation did not have an impact in this context, which is in agree-
ment with the fact that HIV-1 does not need Nef for replication in
T-cell lines. A different picture is observed in primary human
peripheral blood mononuclear cells (PBMC), where HIV-1 repli-
cation is stimulated by Nef (Fig. 5B). In these cells, HIV-rtTA-2A-
nef replicates better than HIV-rtTA-2A-neffs and HIV-rtTA-Ub-nefreplicates much more efﬁciently than HIV-rtTA-Ub-neffs. The rtTA-
Ub-nef virus replicates more efﬁciently than the rtTA-2A-nef var-
iant, which correlates with higher Nef expression (Fig. 2C). Sur-
prisingly, this rtTA-Ub-nef variant replicates even more efﬁciently
than the original HIV-rtTA virus despite the reduced rtTA level of
the Ub variant. This result underlines the strong positive effect of
Nef on viral replication in these cells.
HIV-rtTA-Ub-nef replicates better than HIV-rtTA in human immune
system mice
As HIV-rtTA-Ub-nef replicates more efﬁciently than the other
HIV-rtTA variants in primary T cells, we evaluated the in vivo
replication capacity of this Nef-expressing virus in a human
immune system (HIS) mouse model. Newborn immunodeﬁcient
NOD.scid.IL2Rγc/ (NSG) mice (Shultz et al., 2005) were injected
with CD34þ CD38 human hematopoietic progenitor cells
(hHPCs) to generate NSG-HIS mice that produce all major subsets
of the human innate and adaptive immune system, including T and
B cells, dendritic cells, macrophages and natural killer cells (Shultz
et al., 2005). These mice are susceptible to HIV-1 infection and
several studies have underlined the value of this model for HIV-1
research (Akkina, 2013; Nischang et al., 2012; Watkins et al., 2013;
Zou et al., 2012). The NSG-HIS mice were infected by intraper-
itoneal injection with HIV-rtTA (n¼5), HIV-rtTA-Ub-nef (n¼5) and
the parental HIV-1 LAI strain (n¼4), or were mock infected (n¼4).
To ensure optimal replication of the dox-dependent HIV-rtTA and
HIV-rtTA-Ub-nef on the day of virus injection, regular food was
replaced by dox-containing food 3 days prior to infection. We
monitored the plasma RNA viral load and human CD4þ T-cell
frequency in the blood for 8 weeks.
In all 4 HIV-1 LAI-infected NSG-HIS mice, a rapid increase in
plasma RNA viral load was observed, peaking at 2 weeks post-
infection (p.i.) at 3106 copies/ml (Fig. 6A). In agreement with
this efﬁcient HIV-1 replication, a gradual reduction in the per-
centage of human CD4þ T-cells in the blood was observed as early
as 3 weeks p.i. (Fig. 6B). Only 1 of the 5 HIV-rtTA injected mice was
productively infected, which resulted in a low but detectable level
of plasma viral RNA at 3 weeks p.i. and a slow increase in viral load
in the subsequent weeks. In contrast, 3 of the 5 HIV-rtTA-Ub-nef
injected mice were productively infected. The plasma viral load in
these animals peaked at 4104 copies/ml at 2 weeks p.i. The
frequency of human CD4þ T-cells in the blood of the HIV-rtTA and
HIV-rtTA-Ub-nef infected mice was similar to that of the mock-
infected animals and remained stable. These results demonstrate
that HIV-rtTA-Ub-nef replicates more efﬁciently in NSG-HIS mice
than HIV-rtTA, which is likely attributable to the positive effect of
Nef on in vivo virus replication. HIV-rtTA-Ub-nef does however not
replicate as efﬁciently as the parental HIV-1 LAI strain and does
not cause a decline in human CD4þ T cells (Legrand et al., 2012).
HIV-rtTA-Ub-nef replicated also less efﬁciently than HIV-1 LAI in
SupT1 T cells and primary PBMC (data not shown). This result
indicates that a high virus replication rate is required for CD4þ T-
cell depletion. The attenuated phenotype of HIV-rtTA-Ub-nef is
probably due to the presence of exogenous gene expression ele-
ments (rtTA-tetO and Ub). We indeed measured reduced Nef
production for HIV-rtTA-Ub-nef when compared with LAI (Fig. 2C).Discussion
We previously constructed a dox-controlled HIV-1 variant, HIV-
rtTA, in which the nef gene had been replaced by the gene
encoding the dox-inducible transcriptional activator rtTA. Loss of
Nef function does not compromise virus replication in T-cell lines,
but does affect replication in primary cells and virus-induced
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and IRES-based strategies to restore the Nef function in HIV-rtTA.
The fusion-protein strategy resulted in the HIV-rtTA-2A-nef and
HIV-rtTA-Ub-nef variants that express functional Nef protein. Both
viruses replicate efﬁciently in a T-cell line and primary PBMC, and
stably maintained the introduced nef gene and ﬂanking sequences
in long-term cultures. The HIV-rtTA-Ub-nef variant replicated
more efﬁciently in NSG-HIS mice than the original HIV-rtTA,
resulting more frequently in a productive infection and an earlier
peak of the plasma RNA viral load, which is in agreement with the
positive effect of Nef on in vivo virus replication (Watkins et al.,
2013; Zou et al., 2012).
In HIV-rtTA-2A-nef, the “self-cleavage” activity of the nascent
2A domain will result in the co-translational production of an rtTA
protein with 24 2A-derived amino acids at the C-terminus (rtTA-
2A) and a Nef protein with a 2A-derived proline at the N-terminus
(ProNef). These 2A-additions apparently do not signiﬁcantly affect
rtTA activity (Fig. 4B) and do not block Nef’s capacity to down-
modulate CD4 expression (Fig. 4A). The wild-type Nef protein is
myristoylated during translation, which involves cleavage of the
N-terminal methionine residue and subsequent addition of the
myristoyl group to the N-terminal glycine by N-myristoyl trans-
ferase (Hill and Skowronski, 2005). It seems unlikely that the N-
terminus of the ProNef protein is myristoylated, as this would
require removal of both the proline and methionine residues
before the myristoyl group can be added to the glycine. Such
processing of ProNef would result in wild-type myristoylated Nef
protein, while we observed a small difference in the migration of
wild-type Nef and ProNef in the western blot analysis (Fig. 2C),
consistent with a myristoylation defect of ProNef. Although myr-
istoylation of Nef is important for its association with cellularmembranes and has been reported to inﬂuence most of Nef’s
biological activities (Geyer et al., 2001), several studies demon-
strated signiﬁcant residual Nef activity of non-myristoylated Nef
variants, possibly because other signals within Nef contribute to
membrane binding (Bentham et al., 2006; Fackler et al., 2006;
Hanna et al., 2004). The rtTA-2A-nef virus replicates more efﬁ-
ciently than the corresponding Nef-negative rtTA-2A-neffs variant
in PBMC (Fig. 5B). This result demonstrates that the produced
ProNef protein is functional and able to enhance virus replication in
primary cells. Both viruses replicate with similar efﬁciency in
SupT1 cells (Fig. 5A), which is in agreement with the accessory
role of Nef in this T-cell line.
HIV-rtTA-2A-neffs replicated less efﬁciently than the original
HIV-rtTA in PBMC, which indicates that the 2A-nef sequences have
a negative effect on virus replication. In agreement with this, HIV-
rtTA-2A-nef replicated with comparable efﬁciency as HIV-rtTA in
these cells, despite the stimulatory effect of Nef. The re-introduced
nef sequences may be responsible for the inhibitory effect. These
RNA sequences could bind cellular miRNAs that reduce viral gene
expression (Ahluwalia et al., 2008) or may encode miRNAs that
reduce viral gene expression and inﬂuence cellular genes (Omoto
et al., 2004; Omoto and Fuji, 2005). Alternatively, the overlapping
nef/U3 DNA promoter sequences may bind (negative) transcrip-
tion factors that reduce viral transcription (Stevens et al., 2006).
In HIV-rtTA-Ub-nef, post-translational cleavage of the rtTA-Ub-
nef fusion protein by deubiquitinating enzymes results in an rtTA
protein with 76 Ub-derived amino acids at its C-terminus (rtTA-
Ub) and a wild-type Nef protein. The Ub moiety reduced rtTA
activity (Figs. 2B and 4B), which explains the reduced replication
in SupT1 cells when compared to HIV-rtTA and HIV-rtTA-2A-nef
(Figs. 3 and 5A). HIV-rtTA-Ub-nef replicated much better than the
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viruses replicated with similar efﬁciency in SupT1 cells. These
results are in agreement with the positive effect of Nef on repli-
cation in PBMC but not in SupT1 cells.
HIV-rtTA-Ub-nef replicated more efﬁciently than HIV-rtTA-2A-
nef in PBMC, while the situation was reversed in SupT1 cells
(Fig. 5A and B). Better replication of HIV-rtTA-Ub-nef in PBMC can
be explained by increased Nef production (Fig. 2C), but it may also
indicate that the wild-type Nef protein produced by the Ub variant
is more active than the ProNef mutant protein produced by the 2A
variant. We measured a similar capacity to down regulate CD4 for
the ProNef variant and the wild-type protein upon transfection of
TZM-bl cells with pcDNA3 expression plasmids, but this and other
Nef-associated functions may be affected in primary cells.
Unlike the HIV-rtTA-2A-nef conﬁguration, the HIV-rtTA-Ub-nef
conﬁguration resulted in reduced rtTA transcriptional activity.Although the smaller (24 amino acid) 2A extension of rtTA-2A did
not reduce transcriptional activity, the larger (76 amino acid) Ub
moiety of rtTA-Ub may interfere with the proper exposure of the
transcription activation domain at the C-terminus of rtTA. How-
ever, the reduced rtTA activity of rtTA-Ub may also be due to the
biological activity of the Ub domain, which could trigger protein
degradation (Qian et al., 2002; Varshavsky, 2005).
We also tried different IRES-based approaches to restore Nef
expression in HIV-rtTA and both the 585-nt EMCV-derived IRES
and the synthetic 50-nt PS3 IRES element were tested. All exam-
ined conﬁgurations resulted in high rtTA activity and the pro-
duction of wild-type Nef protein, but nevertheless none of these
variants replicated efﬁciently. Upon culturing on SupT1 cells, the
viruses rapidly lost the introduced IRES and ﬂanking nef sequen-
ces, but kept the rtTA gene intact, resulting in efﬁciently repli-
cating HIV-rtTA variants. The rapid loss of the introduced IRES
elements in all cultures indicates that these sequences are detri-
mental to virus replication. Possibly, introduction of the highly
structured EMCV IRES in the viral RNA genome may halt the
process of reverse transcription (Klasens et al., 1999) or affect the
higher order structure of the viral RNA, which could inﬂuence
processes like splicing and packaging. The nef-IRES-rtTA conﬁg-
uration resulted in reduced CA-p24 production but normal Nef and
rtTA levels, which may suggest a splicing effect, but this was not
investigated further. Surprisingly, also the PS3 element that does
not fold a stable RNA structure inhibited viral replication. Because
the IRES element and downstream ORF will be present at the 30
end of all spliced and unspliced RNAs, the protein will be produced
from all RNAs, which likely results in an aberrant level and timing
of protein expression. For instance, Nef is an early HIV-1 protein
and its expression during the late phase of HIV-rtTA-IRES-nef
replication may be detrimental.
HIV-rtTA-Ub-nef and HIV-rtTA-2A-nef express all HIV-1 pro-
teins and these new virus variants can serve as a research tool to
study the HIV-1 replication cycle and virus-host interactions in
primary cell and tissue culture systems and in the HIS mouse
model. The knowledge gained in this HIV-rtTA study can be used
to improve the dox-dependent SIVmac239 variant (25,26). This
Nef-deﬁcient SIV-rtTA variant is currently being tested in maca-
ques to identify the host responses that protect vaccinated animals
against pathogenic SIV challenge. Preliminary results demonstrate
that SIV-rtTA does replicate in vivo (Manoussaka et al., 2013) and
is able to induce a marked vaccine effect (manuscript in prepara-
tion). Interestingly, the highest level of protection was observed in
vaccinates that exhibit a persisting SIV-rtTA viraemia prior to
challenge, which is in agreement with the inverse correlation
between the level of attenuation and the degree of protection
induced by live-attenuated SIV vaccines (13). It thus seems
important to restore the Nef function in SIV-rtTA, which is
expected to improve the replication of the vaccine strain in
macaques. Nef expression may also result in an additional vaccine
boost because the full complement of the viral proteins is pre-
sented to the immune system.Materials and methods
Construction of Nef-positive HIV-rtTA molecular clones
Construction of the HIV-rtTA molecular clone was described
previously (Das et al., 2004a; Verhoef et al., 2001). All HIV-rtTA
variants used in this study contain the 2Δ15tetO promoter con-
ﬁguration in both the 50 and 30 LTR (Das et al., 2004b; Marzio et al.,
2001, 2002) and the optimized rtTA V16 gene (Zhou et al., 2006b).
This HIV-rtTA plasmid was used for the construction of the HIV-
rtTA-nef molecular clones. An HIV-rtTA variant with a truncated
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in the 50 and 30 LTR (HIV-rtTA-dNF5
0 þ30)(Das et al., 2011) was used
for the construction of the HIV-nef-rtTA clones.
HIV-nef-IRES-rtTA
The 585-nt encephalomyocarditis virus (EMCV)-derived IRES
sequence from pIRES2-EGFP (Clontech) was PCR ampliﬁed with
primers IRES-EcoRI-BBB (ACGAGCGCGCGGATCCAAGATCTCGAA-
TTCGCCCCTCTCCCTCCCCCC; BssHII and EcoRI sites underlined)
and IRES-XcmI-XbaI (TGTCCAGTCTAGACATGGTTGTGGCCATATTA-
TC; XbaI site underlined). The PCR product was digested with
BssHII and XbaI and cloned into the corresponding sites of the
shuttle vector pBlue30LTRextΔU3-rtTA-2ΔtetO-dNFeco (Das et al.,
2011) resulting in pBlue30LTRextΔU3-IRES-rtTA-2ΔtetO-dNFeco.
We subsequently introduced the nef gene in which the TPI
sequence had been synonymously mutated (Munch et al., 2005).
For this, we PCR ampliﬁed the 30 part of nef from the HIV-1 pLAI
plasmid with primers TPI-mut-BglII (CTCTAGATCTTAGCC-
ACTTCCTCAAGGAGAAAGGTGGCCTTGAGGGTCTTATTCACTCCC; sil-
ent TPI mutations in bold; BglII site underlined) and nef-stop-
EcoRI (CTCGAATTCAGCAGTTCTTGAAGTACTC; EcoRI site under-
lined). The PCR product was digested with BglII and EcoRI, com-
bined with the BamHI-BglII 50 nef fragment from pLAI, and ligated
into the BamHI and EcoRI sites of pBlue30LTRextΔU3-IRES-rtTA-
2Δ15tetO-dNFeco, resulting in pBlue30LTRextΔU3-nef-IRES-rtTA-
2Δ15tetO-dNFeco. To construct HIV-nef-IRES-rtTA, the BamHI-
AatII fragment of this shuttle vector was inserted into the corre-
sponding sites of HIV-rtTA-dNF5
0 þ30.
HIV-nef-2A-rtTA and HIV-nef-PS3-rtTA
The nef gene from pBlue30LTRextΔU3-nef-IRES-rtTA-2Δ15tetO-
dNFeco was PCR ampliﬁed with primers nefseq2 (CATGGAG-
CAATCACAAGTAG) and nef-2A-rtTA-rev (CCAGTCTAGA-
CATGGGTCCAGGGTTGGACTCAACGTCACCCGCCAACTTAAGTAGGTCAA-
AGTTCAAGAGCTGTTTTGCCGGCGCAATGCAGTTCTTGAAGTACTCCGG-
ATGCA; XbaI site underlined; 75-nt 2A sequence from foot-and-
mouth disease virus A in italics; isolate A10 Holland; Genbank
AY593751) or nef-PS3-rev (CCAGTCTAGACATCTACAAAAAAATCACG-
CAAAATTACAGTTAACGGCATGTACAGTTTGTCATCAGCAGTTCTTGAAG-
TACTCCGGATGCA; XbaI site underlined; 50-nt PS3 IRES sequence
in italics (Venkatesan and Dasgupta, 2001)). The resulting nef-2A
and nef-PS3 products were digested with DraIII and XbaI, and used
to replace the corresponding nef-IRES fragment in pBlue30L-
TRextΔU3-nef-IRES-rtTA-2Δ15tetO-dNFeco, which resulted in
pBlue3’LTRextΔU3-nef-2A-rtTA-2Δ15tetO-dNFeco and pBlue30L-
TRextΔU3-nef-PS3-rtTA-2Δ15tetO-dNFeco, respectively. The
BamHI-BglI fragment of these shuttle vectors was subsequently
inserted into the corresponding sites of HIV-rtTA-dNF5
0 þ30.
HIV-rtTA-2A-nef
The nef region from pLAI was PCR ampliﬁed with primers rtTA-
2A-nef-fwd (GCTCCCCGGGATTGCGCCGGCAAAACAGCTCTTGAACTTT-
GACCTACTTAAGTTGGCGGGTGACGTTGAGTCCAACCCTGGACCCATGGG-
TGGCAAGTGGTCAAAAAGTAGTG; 75-nt FMDV 2A sequence in ita-
lics; SmaI site underlined) and pLAI30seq (TGTCTCATGAGCGGA-
TACATA). The 2A-nef PCR product was digested with SmaI and
BspEI, and cloned into the corresponding sites of pBlue30L-
TRextΔU3-rtTA-2Δ15tetO (Das et al., 2004b). The BamHI-BglI
fragment of the resulting shuttle vector pBlue30LTRextΔU3-rtTA-
2A-nef-2Δ15tetO was subsequently inserted into the correspond-
ing sites of HIV-rtTA.HIV-rtTA-IRES-nef
The EMCV IRES sequence was PCR ampliﬁed from pBlue30L-
TRextΔU3-nef-IRES-rtTA-2Δ15tetO-dNFκB with primers rtTA-
IRES-fwd (GCTCCCCGGGTAAATTCGCCCCTCTCCCTCCCC; SmaI site
underlined) and IRES-nef-rev (TGCCACCCATGGTTGTGGCCA-
TATTATCATC). The nef sequence was PCR ampliﬁed from
pBlue30LTRextΔU3-rtTA-2A-nef-2Δ15tetO with the primers IRES-
nef-fwd (GGCCACAACCATGGGTGGCAAGTGGTCAAAAAG) and CN1
(GGTCTGAGGGATCTCTAGTTACCAGAGTC). The IRES and nef PCR
products, which have sequences that partially overlap, were mixed
and used as template in a PCR with the outer primers rtTA-EMCV-
fwd and CN1. The resulting IRES-nef fragment was digested with
SmaI and BspEI, and ligated into the corresponding sites of
pBlue30LTRextΔU3-rtTA-2Δ15tetO. The BamHI-PvuI fragment of
the resulting pBlue30LTRextΔU3-rtTA-IRES-nef-2Δ15tetO shuttle
vector was subsequently inserted into the corresponding sites of
HIV-rtTA.
HIV-rtTA-Ub-nef
The ubiquitin (Ub) sequence was PCR ampliﬁed from plasmid
pExoIn (Matentzoglu and Scheffner, 2009) with primers rtTA-ubi-
fwd (GCTCCCCGGGATGCAGATTTTCGTCAAGAC; SmaI site under-
lined) and nef-ubi-rev (TTTGACCACTTGCCACCCATCCCACCTCTAA-
GACGGAGC) and the nef sequence was PCR ampliﬁed from
pBlue30LTRextΔU3-rtTA-2A-nef-2Δ15tetO with the primers ubi-
nef-fwd (GCTCCGTCTTAGAGGTGGGATGGGTGGCAAGTGGTCAAA)
and anti-U3-att (GGAGTGAATTAGCCCTTCCA). The partially over-
lapping Ub and nef PCR products were mixed and PCR ampliﬁed
with the primers rtTA-ubi-fwd and anti-U3-att. The Ub-nef PCR
product was digested with SmaI and BglII, and cloned into the
corresponding sites of pBlue30LTRextΔU3-rtTA-2A-nef-2Δ15tetO,
which resulted in pBlue30LTRextΔU3-rtTA-Ub-nef-2Δ15tetO. The
BamHI-BglI fragment of this shuttle was inserted into the corre-
sponding sites of HIV-rtTA.
Construction of pcDNA3 expression vectors
The rtTA, rtTA-nef and nef-rtTA DNA sequences were PCR
ampliﬁed from the various HIV-rtTA plasmids with the sense
primer BamHI-rtTA-fwd (CTCGGATCCATGTCTAGACTGGACAA-
GAGC; BamHI site underlined) or BamHI-nef-fwd (CTCGGATC-
CATGGGTGGCAAGTGGTCAAA; BamHI site underlined) and the
antisense primer NotI-nef-rev (CGAGCGGCCGCTCAGCAGTTCTT-
GAAGTAC; NotI site underlined) or NotI-rtTA-rev (CGAGCG-
GCCGCTTACCCGGGGAGCATGTCAAGGTCA; NotI site underlined).
Similarly, the wild-type nef gene was PCR ampliﬁed from pLAI
with primers BamHI-nef-fwd and NotI-nef-rev. All PCR products
were digested with BamHI and NotI, and ligated into the corre-
sponding sites downstream of the human cytomegalovirus
immediate-early (CMV IE) enhancer and promoter region in
plasmid pcDNA3 (Invitrogen).
Cell culture
The TZM-bl cell line was obtained from John C. Kappes,
Xiaoyun Wu, and Tranzyme Inc. (Durham, NC) through the NIH
AIDS Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH. TZM-bl cells and 293 T cells were grown at 37 °C and
5% CO2 in Dulbecco's modiﬁed Eagle's medium containing 10%
fetal bovine serum (FBS), minimal essential medium nonessential
amino acids, 100 U/ml penicillin, and 100 mg/ml streptomycin.
SupT1 T cells were grown at 37 °C and 5% CO2 in RPMI 1640
advanced medium containing 1% FBS, 100 U/ml penicillin and
100 mg/ml streptomycin. Human peripheral blood mononuclear
cells (PBMC) were isolated from fresh buffy coats by standard
Ficoll–Hypaque density centrifugation and controlled by PCR for
Y.U. van der Velden et al. / Virology 488 (2016) 96–107 105the absence of the CCR5 Δ32 allele. Cells isolated from 4 donors
were pooled and aliquots were stored at 152 °C. When required,
cells were thawed and cultured in RPMI medium supplemented
with 10% FBS, 100 U/ml penicillin, 100 mg/ml streptomycin, 100 U/
ml recombinant IL-2 and 1 mg/ml phytohemagglutinin (PHA) for
3 days. Cells were cultured in the same medium without PHA for
3 days and subsequently infected with the HIV-1 variants.
FACS analysis
TZM-bl cells were cultured in 10-cm2 wells to 60% conﬂuency.
Cells were transfected with 5 mg of pcDNA3 vector using lipo-
fectamin (Invitrogen) according to the manufacturer’s protocol.
Cells were collected by trypsinization and ﬁxated in 250 μl 4%
formaldehyde for 5 min at room temperature. Cells were washed
with FACS buffer (PBS containing 2% FBS) and incubated for 2 h
with 10 μl CD4-PE 1:10 (clone MT310, DakoCytomation). Excess
antibody was removed by washing the cells with FACS buffer. Cells
were resuspended in 300 μl FACS buffer and the CD4-PE mean
ﬂuorescence intensity (MFI) was analyzed on a FACScalibur ﬂow
cytometer with CellQuest Pro software (BD biosciences). The data
from different experiments was corrected for between-session
variation with the factor correction program (Ruijter et al., 2006).
rtTA activity assay and virus production
For the rtTA activity assay, 293 T cells were cultured in 2-cm2
wells to 60% conﬂuency and transfected by the calcium phosphate
method with 20 ng pLTR-2tetO-lucff construct (Das et al., 2004b),
0.5 ng pRL-CMV (Promega) and 1 mg DNA, which was either 1 mg
HIV-rtTA plasmid or 0.5 ng pcDNA3 vector plus 999.5 ng pBlue-
script SKþ . The plasmid pRL-CMV, in which the expression of
Renilla luciferase is controlled by the CMV IE promoter, was co-
transfected to allow correction for differences in transfection
efﬁciency. The DNA in a total volume of 22 ml water was mixed
with 25 ml of 2x HBS (50 mM HEPES pH 7.1, 250 mM NaCl, 1.5 mM
Na2HPO4) and 3 ml 2 M CaCl2, incubated at room temperature for
20 min, and added to the culture medium. The cells were cultured
without or with 1 mg/ml dox (Sigma D-9891) and the culture
medium was refreshed after 16 h. The cells were lysed in passive
lysis buffer after 48 h and the ﬁreﬂy and Renilla luciferase activity
were determined with a dual-luciferase assay (Promega). The rtTA
activity was calculated as the ratio between the ﬁreﬂy and Renilla
luciferase activity. For the production of virus stocks, cells were
transfected with 1 mg of the HIV-rtTA constructs (as described
above) and cultured with 1 mg/ml dox. After 48 h, the CA-p24 level
in culture supernatant samples was measured by ELISA. The data
from different experiments was corrected for between-session
variation with the factor correction program (Ruijter et al., 2006).
Virus replication
5106 SupT1 cells were transfected with 5 mg of the HIV-rtTA
plasmids by electroporation and cultured in 5 ml of medium with
1 mg/ml dox, as previously described (Das et al., 2004b). Cells were
split 1–5 twice a week. PBMC (1106 cells in 0.5 ml culture med-
ium) were infected with 293 T-produced virus (5 ng CA-p24). Cells
were cultured in the presence of 1 mg/ml dox and half the culture
medium was refreshed every 3–4 days. Viral replication was mon-
itored by measuring the CA-p24 level in the culture supernatant.
CA-p24 antigen ELISA
Culture supernatant was heat-inactivated at 56 °C for 30 min in
the presence of 0.05% Empigen-BB (Calbiochem). CA-p24 con-
centration was determined by a twin-site ELISA with D7320
(Biochrom) as the capture antibody and alkaline phosphatase-
conjugated anti-p24 monoclonal antibody (EH12-AP) as the
detection antibody. Detection was done with the lumiphos plus
system (Lumigen) in a LUMIstar Galaxy luminescence reader (BMGlab technologies). Recombinant CA-p24 produced in a baculovirus
system was used as the reference standard.
Proviral DNA analysis
Infected cells were pelleted by centrifugation at 4000 rpm for
4 min and washed with PBS. DNA was solubilized by resuspending
the cells in 10 mM Tris–HCl pH 8.0, 0.1 mM EDTA, 0.5% Tween-20,
followed by incubation with 200 mg/ml proteinase K at 56 °C for
60 min and 95 °C for 10 min. Proviral DNA sequences were PCR
ampliﬁed from total cellular DNA and the size of PCR fragments was
analyzed on a 1% agarose gel. In addition, sequence analysis was
performed by bigdye terminator cycle sequencing (PE Biosystems).
Western blot analysis
293 T cells were transfected with HIV-rtTA molecular clones as
described for virus production. Cells were washed with PBS after
48 h and lysed in 150 ml sample buffer (4% SDS, 20% glycerol, 2.5% ß-
mercaptoethanol, 125 mM Tris–HCl pH 6.8 and 0.003% bromophe-
nol blue). Proteins were separated by 10% SDS-PAGE and transferred
to Immobilon-P membranes (Millipore) by electroblotting. Blots
were stained with HIV-1 Nef antiserum (Shugars et al., 1993), which
was obtained from Dr. Ronald Swanstrom through the NIH AIDS
Research and Reference Reagent Program, Division of AIDS, NIAID,
NIH. Bound antibodies were visualized with peroxidase-linked anti-
rabbit IgG and the ECLþ kit (Amersham Biosciences) and analyzed
with the LAS-3000 imaging system (Fujiﬁlm).
Isolation of human hematopoietic progenitor cells (hHPCs) and gen-
eration of HIS mice
Fetal liver material was collected with informed consent and its
use approved by the Medical Ethical Committee of the Academic
Medical Center of the University of Amsterdam. hHPCs were enri-
ched by immunomagnetic beads (Miltenyi Biotech), followed by cell
sorting using a FACSAria (BD Biosciences) to obtain
CD34þCD38CD3CD19CD56BDCA2 hHPCs at a purity of
Z99%. Puriﬁed hHPCs were stored in liquid nitrogen until use. NOD.
scid.IL2Rγc / (NSG) mice (Shultz et al., 2005) were generated as
described previously (Centlivre et al., 2013). Brieﬂy, newborn NSG
mice were irradiated within a week after birth with 1 Gy and
thereafter received 5105 hHPCs intra-hepatically. Around 8 weeks
after transplantation, engraftment of human cells was evaluated.
Mice were considered successfully engrafted based on a minimum
of 20% human CD45þ cells in their peripheral blood. All animal
experiments were approved by the Animal Ethical Committee of
the Academic Medical Center of the University of Amsterdam.
Infection of HIS mice, viral load and FACS analysis
NSG-HIS mice (12–15 weeks old) were injected intraper-
itoneally with an equal amount of HIV-1 LAI, HIV-rtTA or HIV-
rtTA-Ub-nef, as described previously (Legrand et al., 2012). To
allow replication of rtTA variants, dox-containing food (2 g/kg;
BioServ) was administered to the mice, starting three days prior to
infection. Results of the two independent experiments were
grouped. Plasma samples were collected at several times after
infection. Plasma viral RNA was extracted by QIAamp Viral RNA
Mini Kit (Qiagen) and viral load was determined by quantitative
RT-PCR (Pasternak et al., 2008), with the omittance of the lineair
PCR and the detection limit set at 5 copies/per reaction. For FACS
analysis, red blood cells were lysed and peripheral blood mono-
nuclear cells (PBMCs) were ﬁxed in 1% formaldehyde for 30 min-
utes at room temperature. Cell suspensions were labeled with rat
anti-mouse CD45-BV650 (30-F11) and the following mouse anti-
human monoclonal antibodies: CD45APC-H7 (2D1), CD3-V500
(UCHT1), CD4-PerCP-Cy5.5 (RPA-T4) and CD8-BV421 (RPA-T8).
All antibodies were purchased from BD Biosciences and samples
Y.U. van der Velden et al. / Virology 488 (2016) 96–107106were analyzed with a LSR Fortessa (BD Biosciences) cell analyzer
interfaced to the FACS-Diva software system.Acknowledgments
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